Loading clinical trials...

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial | Clinical Trials | Clareo Health

RECRUITINGNA

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)

NCT05975593•Washington University School of Medicine

View on ClinicalTrials.gov

Summary

This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Confirmation of intent to receive radiotherapy for one of the following diagnoses:
•* Cervical cancer
•* Pancreatic cancer
•ECOG performance status ≤ 2
•At least 18 years old
•Able to understand and willing to sign an IRB-approved written informed consent document

Exclusion Criteria

•Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Key Dates

Start Date

January 11, 2024

Primary Completion Date

December 31, 2032

Completion Date

December 31, 2032

Last Updated

November 12, 2025

Enrollment

ESTIMATED participants

Conditions

Locally Advanced Cervical CarcinomaLocally Advanced Cervical CancerLocally Advanced Pancreas CancerLocally Advanced Pancreatic CarcinomaLocally Advanced Pancreatic CancerCervical CancerPancreas CancerPancreatic CancerCancer of the CervixCancer of the Pancreas

Interventions

Tumor collection via biopsy

OTHER

Blood collection

OTHER

Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)

DEVICE

Contacts

Cliff Robinson, M.D.

CONTACT

314-362-8567 clifford.robinson@wustl.edu

Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

NCT07104149

Female, Age ≥ 18 Years OldNo Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy+7 more

View study

RECRUITINGNA

PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer

NCT05406856

Uterine Cervical NeoplasmsLocally Advanced Cervical Carcinoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 12, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

Inclusion Criteria

Exclusion Criteria

Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer

Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer

Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)